Table 4.
Univariable | Bivariable: BioADM | Bivariable: PenKid | |||||||
OR | 95% CI | P value | OR | 95% CI | P value | OR | 95% CI | P value | |
Age | 1.04 | 0.99 to 1.09 | 0.067 | 1.54 | 1.03 to 2.31 | 0.037 | 2.16 | 1.49 to 3.13 | <0.001 |
Sex | 0.53 | 0.24 to 1.16 | 0.112 | 1.58 | 1.05 to 2.37 | 0.028 | 2.19 | 1.53 to 3.14 | <0.001 |
Diabetes | 0.85 | 0.37 to 1.92 | 0.689 | 1.52 | 1.01 to 2.28 | 0.045 | 2.23 | 1.56 to 3.19 | <0.001 |
SBP | 0.99 | 0.98 to 1.01 | 0.254 | 1.48 | 0.98 to 2.25 | 0.063 | 2.28 | 1.59 to 3.27 | <0.001 |
ACE-i | 0.60 | 0.26 to 1.36 | 0.217 | 1.49 | 0.99 to 2.23 | 0.056 | 2.24 | 1.56 to 3.21 | <0.001 |
ARB | 0.92 | 0.46 to 1.81 | 0.798 | 1.51 | 1.01 to 2.27 | 0.049 | 2.27 | 1.58 to 3.25 | <0.001 |
Betablockers | 0.20 | 0.09 to 0.46 | <0.001 | 1.61 | 1.08 to 2.40 | 0.020 | 2.08 | 1.44 to 3.00 | <0.001 |
Prior HF | 0.54 | 0.25 to 1.19 | 0.127 | 1.63 | 1.09 to 2.46 | 0.018 | 2.22 | 1.56 to 3.15 | <0.001 |
Creatinine | 1.77 | 1.27 to 2.46 | 0.001 | 1.38 | 0.90 to 2.11 | 0.139 | 2.31 | 1.51 to 3.53 | <0.001 |
BNP | 1.28 | 0.85 to 1.92 | 0.235 | 1.42 | 0.93 to 2.15 | 0.105 | 2.29 | 1.56 to 3.35 | <0.001 |
Smoking | 0.43 | 0.10 to 1.84 | 0.255 | 1.47 | 0.97 to 2.21 | 0.067 | 2.25 | 1.57 to 3.23 | <0.001 |
Prevalent AF | 0.47 | 0.20 to 1.09 | 0.078 | 1.50 | 1.01 to 2.25 | 0.047 | 2.18 | 1.53 to 3.11 | <0.001 |
Bio-ADM | 1.50 | 1.00 to 2.26 | 0.051 | 2.19 | 1.52 to 3.15 | <0.001 | |||
penKid | 2.24 | 1.57 to 3.20 | <0.001 | 1.34 | 0.88 to 2.03 | 0.168 |
Values are OR with 95% CI. All results are reported for the pooled cohort (n=470, 24 events). Univariable results are presented as each variable’s associations with in-hospital mortality. Bivariable results are reported for penKid and bio-ADM, adjusted for each variable separately.
ACE-I, ACE inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; Bio-ADM, bioactive adrenomedullin; HF, heart failure; SBP, systolic blood pressure; penKid, proenkephalin A 119–159.